Search
                    Tirzepatide Treatment Options in Tucson, AZ
A collection of 6 research studies where Tirzepatide is the interventional treatment. These studies are located in the Tucson, AZ. Tirzepatide is used for conditions such as Obesity, Overweight and Type 2 Diabetes.
            1 - 6 of 6
        
        
    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Lose Weight with Tirzepatide
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to tirzepatide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss.
    Semaglutide and Tirzepatide are advanced GLP-1 medications designed to support weight management and metabolic health. They work by targeting GLP-1 receptors in the body, helping regulate appetite, improve blood sugar control, and support sustainable weight loss.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    Featured Trial
                
                Paid Clinical Studies Nationwide
            
        Recruiting
            
        Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
    
    
Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    
                
                                    A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
                                
            
            
        Active Not Recruiting
                            
            
                This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medicine. Doctors cannot yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide. Doctors can prescribe tirzepatide in some countries. Participants will either receive CagriSema or tirzepatide. Which treatment the participant will receive is decided by chance. For each participant, the study will last for up to 1 year and 4...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                08/21/2025
            
            Locations: Velocity Clinical Research-Phoenix, Phoenix, Arizona  +1 locations         
        
        
            Conditions: Diabetes Mellitus, Type 2
        
            
        
    
                
                                    A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
                                
            
            
        Recruiting
                            
            
                The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for chronic weight management alone or in combination with Tirzepatide across a wide dose range in participants with Type 2 Diabetes. Participation in the study will last about 64 weeks.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 75 years
            Trial Updated:
                07/22/2025
            
            Locations: The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler, Arizona  +3 locations         
        
        
            Conditions: Obesity, Overweight
        
            
        
    
                
                                    A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
                                
            
            
        Recruiting
                            
            
                The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newly enrolled participants across the master and the ISAs. The ISAs may start independently of other ISAs as interventions become available for clinical testing. The results for the CWMM screening record...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 75 years
            Trial Updated:
                07/17/2025
            
            Locations: The Institute for Liver Health II dba Arizona Clinical Trials - Mesa, Chandler, Arizona  +3 locations         
        
        
            Conditions: Obesity, Overweight
        
            
        
    
                
                                    A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)
                                
            
            
        Recruiting
                            
            
                The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe PsA and obesity or overweight with at least 1 weight-related comorbidity.
The study will last up to 12 months.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/17/2025
            
            Locations: AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Avondale, Avondale, Arizona  +9 locations         
        
        
            Conditions: Psoriatic Arthritis, Overweight or Obesity
        
            
        
    
                
                                    A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
                                
            
            
        Active Not Recruiting
                            
            
                This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additional evidence for the potential clinical benefits of tirzepatide in this population.             
        
        
    Gender:
                ALL
            Ages:
                40 years and above
            Trial Updated:
                07/01/2025
            
            Locations: Prime Medical Group, LLC dba Gilbert Center for Family Medicine, LLC, Gilbert, Arizona  +3 locations         
        
        
            Conditions: Obesity, Overweight
        
            
        
    
                
                                    Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
                                
            
            
        Active Not Recruiting
                            
            
                The main purpose of this study is to demonstrate that when participants with psoriatic arthritis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriatic arthritis and achieve weight reduction compared to when receiving ixekizumab.
Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatmen...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 80 years
            Trial Updated:
                07/01/2025
            
            Locations: AARA Clinical Research - Arizona Arthritis & Rheumatology Associates - Avondale, Avondale, Arizona  +9 locations         
        
        
            Conditions: Psoriatic Arthritis, Obesity
        
            
        
    1 - 6 of 6
            
            
        